Terminated trial offered continued access to rare blood disorder drug
NCT ID NCT05741346
Summary
This study provided continued access to the experimental drug BCX9930 for 28 people with paroxysmal nocturnal hemoglobinuria (PNH), a rare and serious blood disorder. Participants had previously benefited from BCX9930 in earlier studies and didn't have other treatment options. The main goal was to monitor the long-term safety of continued BCX9930 treatment for up to 96 weeks, though the study was ultimately terminated.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigative Site
Paris, France
-
Investigative Site
Budapest, Hungary
-
Investigative Site
Ampang, Malaysia
-
Investigative Site
Bloemfontein, South Africa
-
Investigative Site
Cape Town, South Africa
-
Investigative Site
Pretoria, South Africa
-
Investigative Site
Daejeon, South Korea
-
Investigative Site
Barcelona, Spain
-
Investigative Site
Valencia, Spain
-
Investigative Site
Leeds, United Kingdom
-
Investigative Site
London, United Kingdom
Conditions
Explore the condition pages connected to this study.